Insulet Corporation (PODD) Valuation
Historical valuation analysis based on 1279 data points (2021-09-14 to 2026-10-16)
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposa...
Insulet Corporation (PODD) currently trades at a P/E ratio of 26.07 (historical range: 24.11–38579.67, median: 89.00), placing it at the 3th percentile — cheap relative to its history, P/S ratio of 3.20 (range: 2.96–20.63, 2th percentile — cheap relative to its history), EV/EBITDA of 19.78 (range: 18.35–336.81, 12th percentile).
Over the historical period (2021-09-14 to 2026-10-16), Insulet Corporation's P/E ratio has contracted by 99% over the observed period (from an average of 4860.4 to 56.0).
Insulet Corporation trades well below its historical valuation range across most metrics.
Historical Valuation Metrics
| Metric | Current | Median | %ile | Assessment |
|---|---|---|---|---|
| P/E Ratio | 26.07 | 89.00 | 3th | cheap relative to its history |
| P/S Ratio | 3.20 | 9.69 | 2th | cheap relative to its history |
| EV/EBITDA | 19.78 | 257.44 | 12th | cheap relative to its history |
| FCF Yield | 3.00% | 1.26% | 91th | cheap relative to its history |
Insulet Corporation (PODD) Valuation & P/E History
Insulet Corporation (PODD) is a US-listed stock operating in the Healthcare sector, specifically the Surgical & Medical Instruments & Apparatus industry currently trading at $140.96 with a market capitalization of $9.8 billion. This page provides historical valuation analysis for PODD based on 1279 data points covering 2021-09-14 to 2026-10-16. The P/E ratio of 26.07 is below the historical median of 89.00, placing PODD at the 3th percentile of its valuation range. The P/S ratio of 3.20 compares to a median of 9.69.
PODD Valuation Metrics & Historical Range
The valuation table above shows Insulet Corporation's current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether PODD is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests PODD is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for Insulet Corporation.
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is PODD Overvalued or Undervalued?
Insulet Corporation trades well below its historical valuation range across most metrics. The overall valuation percentile of 6 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive PODD is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full PODD analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.PODD trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.